Global Health Limited (MEDANTA) AI Stock Analysis

• Market Cap: ₹372.21B
• Dividend Yield: 0.04%
• Average Volume (3M): 17.50K
• Price to Earnings (P/E): 69.0
• Beta (1Y): 0.50
• Revenue Growth: 15.42%
• EPS Growth: 10.66%
• Country: IN
• Employees: 9,052
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 5.60
• Shares Outstanding: 268,790,370
• 10 Day Avg. Volume: 39,597
• 30 Day Avg. Volume: 17,497
• PEG Ratio: 101.90
• Price to Book (P/B): 9.77
• Price to Sales (P/S): 8.96
• P/FCF Ratio: 308.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,417.50
• Price Target Upside: 4.60% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 71 Outperform
• Price Target: ₹1,520.00 ▲(12.16% Upside)

Global Health Limited's strong financial performance is the most significant factor, supported by robust revenue and profit growth, efficient operations, and a stable balance sheet. Technical analysis indicates a positive trend, though valuation concerns due to a high P/E ratio and low dividend yield slightly dampen the overall score. The absence of earnings call data and corporate events does not impact the score.

Global Health Limited Business Overview & Revenue Model

Company Description

Global Health Limited, a multi-specialty tertiary care provider, offers healthcare services in India. The company primarily offers treatments in the areas of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. It operates a network of four hospitals in Gurugram, Indore, Ranchi, and Lucknow under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurgaon, India.

How the Company Makes Money

Medanta generates revenue through a diverse range of channels, primarily by providing inpatient and outpatient medical services, surgical procedures, diagnostic testing, and wellness programs. The hospital charges patients for room stays, consultations, treatments, and advanced procedures. Additionally, Medanta earns income from its specialized clinics and health packages aimed at preventive care. The company may also benefit from partnerships with insurance companies, enabling it to offer cashless treatment options for insured patients, thus attracting a larger customer base. Furthermore, Medanta engages in medical tourism, drawing international patients seeking high-quality healthcare at competitive prices, which constitutes a significant revenue stream.

Global Health Limited Financial Statement Overview

Summary

Global Health Limited exhibits strong financial health with impressive revenue and profit growth, efficient operations, and a stable balance sheet with prudent leverage. While cash flow management is generally positive, fluctuations in free cash flow warrant attention.

Income Statement

Global Health Limited has demonstrated robust revenue growth with a consistent increase over the years, notably a 12.74% increase from 2024 to 2025. The gross profit margin remains strong, reflecting efficient cost management. The net profit margin has improved slightly, indicating enhanced profitability. The company shows strong EBIT and EBITDA margins, suggesting efficient operations and a healthy operating profit.

Balance Sheet

The company maintains a solid balance sheet with a favorable debt-to-equity ratio of 0.21, indicating prudent leverage management. The return on equity (ROE) is strong at 14.21%, showcasing effective use of equity to generate profits. The equity ratio is high at 71.05%, suggesting a stable capital structure with substantial equity financing.

Cash Flow

Global Health Limited has a positive operating cash flow, consistently covering net income, which indicates effective cash management from operations. However, free cash flow growth has been volatile, with a significant decrease in 2025, highlighting potential risks in capital expenditures. The operating cash flow to net income ratio is strong, demonstrating efficient cash generation relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	38.62B	36.92B	32.75B	26.94B	21.67B	14.29B
Gross Profit	27.48B	19.88B	17.17B	20.69B	16.24B	10.81B
EBITDA	9.91B	8.77B	8.72B	6.78B	4.90B	2.28B
Net Income	5.34B	4.81B	4.78B	3.26B	1.96B	288.05M
Balance Sheet
Total Assets	0.00	47.66B	43.04B	41.16B	31.46B	26.94B
Cash, Cash Equivalents and Short-Term Investments	11.22B	10.51B	11.56B	12.60B	5.12B	2.89B
Total Debt	0.00	7.18B	8.02B	11.22B	11.09B	9.31B
Total Liabilities	-33.88B	13.79B	13.98B	16.88B	15.30B	13.12B
Stockholders Equity	33.88B	33.86B	29.06B	24.28B	16.16B	13.82B
Cash Flow
Free Cash Flow	0.00	1.07B	3.33B	4.09B	367.87M	960.32M
Operating Cash Flow	0.00	6.24B	6.12B	6.45B	3.11B	2.42B
Investing Cash Flow	0.00	-7.21B	-4.41B	-3.42B	-4.21B	-2.39B
Financing Cash Flow	0.00	-972.26M	-5.14B	3.46B	1.60B	-807.23M

Global Health Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1355.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDANTA, the sentiment is Neutral. The current price of 1355.2 is below the 20-day moving average (MA) of 1355.49, below the 50-day MA of 1363.19, and above the 200-day MA of 1239.77, indicating a neutral trend. The MACD of 2.48 indicates Positive momentum. The RSI at 49.50 is Neutral, neither overbought nor oversold. The STOCH value of 20.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:MEDANTA.

Global Health Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDANTA	―	₹372.21B	68.98	―	0.04%	15.42%	10.66%
NH	―	₹362.74B	45.97	―	0.25%	12.09%	-2.79%
KIMS	―	₹288.08B	76.52	―	―	24.71%	19.17%
FORTIS	―	₹824.98B	94.33	―	0.09%	14.04%	32.99%
ASTERDM	―	₹364.14B	110.81	―	0.71%	-53.19%	-94.01%
METROPOLIS	―	₹98.98B	64.71	―	―	12.86%	10.42%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Global Health Limited Corporate Events

Global Health Limited Secures Land for New Hospital in Assam

Global Health Limited has announced that it has secured a 3.5-acre land allotment from Assam Industrial Development Corporation Limited for the construction of a new hospital in Guwahati, Assam. This development marks a significant step in the company’s expansion strategy, as it plans to initiate construction activities in phases, potentially enhancing its market positioning and service reach in the northeastern region of India.

Global Health Limited Secures Land for New Hospital in Guwahati

Global Health Limited has received an in-principle approval from the Assam Industrial Development Corporation Limited for the allotment of 3.5 acres of land in Guwahati, Assam, to establish a new hospital. This strategic move is part of the company’s expansion efforts to increase its healthcare footprint in the region, potentially enhancing its market position and offering improved healthcare services to the local population.

Global Health Limited Announces Virtual AGM for 2025

Global Health Limited has announced the details of its 21st Annual General Meeting, which is scheduled to take place on September 19, 2025, via video conferencing. This move aligns with regulatory compliance and ensures shareholder engagement despite potential physical meeting constraints, reflecting the company’s adaptability and commitment to transparent communication with its stakeholders.

Global Health Limited Releases Q1 FY 2026 Earnings Call Transcript

Global Health Limited has released the transcript of its Earnings Conference Call for the first quarter of the fiscal year 2026, which ended on June 30, 2025. The disclosure, made in compliance with SEBI regulations, is aimed at providing transparency and insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder relations.